Metabolic disease models
Studies indicate that the rising incidence rates of metabolic diseases currently represent the primary risk affecting global health. JOINN's metabolic disease research team has extensive experience in the preclinical development of drugs targeting metabolic disorders and has established disease models for metabolism-related conditions, including obesity, diabetes and its complications, hyperlipidemia and atherosclerosis, hyperuricemia, and gout. These models support comprehensive evaluations of therapeutic interventions in metabolic disease research.
|
?Indication |
?Model |
?Species |
|
?Obesity |
?Diet-induced Obesity (DIO) |
?mice |
|
?cynomolgus monkey |
||
|
?Ob/Ob mice |
?Ob/Ob mice |
|
|
?Type 1 diabetes mellitus |
?STZ-induced T1DM |
?rat, mice |
|
?cynomolgus monkey |
||
|
?Type 2 diabetes mellitus? |
?db/db mice |
?db/db mice |
|
?ZDF rat |
?ZDF rat |
|
|
?STZ + HFD-induced T2DM |
?mice |
|
|
?Spontaneous T2DM |
?cynomolgus monkey |
|
|
?Euglycaemic clamp |
?Beagle dog |
|
|
?Hyperlipidemia/ Hypercholesterolemia |
?HFHC diet |
?ApoE mice |
|
?Golden hamster |
||
|
?cynomolgus monkey |
||
|
?Atherosclerosis |
?HFHC diet |
?ApoE mice |
|
?HFHC diet + mechanical vessel?injury |
?rabbit |
|
|
?cynomolgus?monkey |
||
|
?Hyperuricemia |
?Spontaneous hyperuricemia |
?UOX mice |
|
??Induction of hyperuricemia |
?SD rat |
